MESO Q3 2023 Earnings — Mesoblast Limited Revenue & Financial Results | Market Cap Arena

MESOMesoblast Limited

$2B

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M-3.6% YoY

Gross Profit

-$11M-586.5% margin

Operating Income

-$14M-745.9% margin

Net Income

-$19M-959.3% margin

EPS (Diluted)

$-0.25

QoQ Revenue Growth

-2.1%

Cash Flow

Operating Cash Flow

-$16M

Free Cash Flow

-$16M

Stock-Based Comp.

$791,000

Balance Sheet

Total Assets

$650M

Total Liabilities

$168M

Stockholders' Equity

$482M

Cash & Equivalents

$48M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$2M	-3.6%
Gross Profit	-$11M	-$12M	+3.9%
Operating Income	-$14M	-$19M	+25.2%
Net Income	-$19M	-$21M	+12.7%